ALN-6400: ALN-6400 will be administered subcutaneously (SC)
Placebo: Placebo will be administered subcutaneously (SC)
The purpose of this study is to:
* evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers
* evaluate the efficacy, safety, tolerability and PD of multiple doses of ALN-6400 in adult patients with HHT
| Facility | City | Region | Status |
|---|---|---|---|
| Clinical Trial Site | Birmingham | Alabama | |
| Clinical Trial Site | Cypress | California | |
| Clinical Trial Site | Gainesville | Florida | |
| Clinical Trial Site | Indianapolis | Indiana | |
| Clinical Trial Site | Boston | Massachusetts | |
| Clinical Trial Site | Rochester | Minnesota | |
| Clinical Trial Site | St Louis | Missouri | |
| Clinical Trial Site | Chapel Hill | North Carolina | |
| Clinical Trial Site | Camperdown | Australia | |
| Clinical Trial Site | Parkville | Australia | |
| Clinical Trial Site | Mount Royal | Canada | |
| Clinical Trial Site | Toronto | Canada | |
| Clinical Trial Site | Bordeaux | France | |
| Clinical Trial Site | Bron | France | |
| Clinical Trial Site | Homburg | Germany | |
| Clinical Trial Site | L'Hospitalet de Llobregat | Spain |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06659640 on ClinicalTrials.gov ↗ ← All trials in the USA